SNDX
Price
$20.79
Change
+$0.11 (+0.53%)
Updated
Sep 4, 11:46 AM (EDT)
Capitalization
1.85B
55 days until earnings call
Intraday BUY SELL Signals
VKTX
Price
$34.10
Change
+$0.12 (+0.35%)
Updated
Sep 4, 11:06 AM (EDT)
Capitalization
3.96B
54 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SNDX vs VKTX

SNDX vs VKTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
SNDX vs. VKTX commentary
Sep 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SNDX is a StrongBuy and VKTX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2026
Stock price -- (SNDX: $20.68 vs. VKTX: $33.98)
Brand notoriety: SNDX and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SNDX: 127% vs. VKTX: 67%
Market capitalization -- SNDX: $1.85B vs. VKTX: $3.96B
SNDX [@Biotechnology] is valued at $1.85B. VKTX’s [@Biotechnology] market capitalization is $3.96B. The market cap for tickers in the [@Biotechnology] industry ranges from $141.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SNDX’s FA Score shows that 1 FA rating(s) are green whileVKTX’s FA Score has 0 green FA rating(s).

  • SNDX’s FA Score: 1 green, 4 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, both SNDX and VKTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SNDX’s TA Score shows that 4 TA indicator(s) are bullish while VKTX’s TA Score has 4 bullish TA indicator(s).

  • SNDX’s TA Score: 4 bullish, 7 bearish.
  • VKTX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, VKTX is a better buy in the short-term than SNDX.

Price Growth

SNDX (@Biotechnology) experienced а +2.58% price change this week, while VKTX (@Biotechnology) price change was +0.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.95%. For the same industry, the average monthly price growth was +6.49%, and the average quarterly price growth was +2396.78%.

Reported Earning Dates

SNDX is expected to report earnings on Oct 29, 2026.

VKTX is expected to report earnings on Oct 28, 2026.

Industries' Descriptions

@Biotechnology (+0.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VKTX($3.96B) has a higher market cap than SNDX($1.85B). SNDX YTD gains are higher at: -1.571 vs. VKTX (-3.411). SNDX has higher annual earnings (EBITDA): -205.66M vs. VKTX (-559.57M). VKTX has more cash in the bank: 502M vs. SNDX (361M). VKTX has less debt than SNDX: VKTX (4.09M) vs SNDX (345M). SNDX has higher revenues than VKTX: SNDX (217M) vs VKTX (0).
SNDXVKTXSNDX / VKTX
Capitalization1.85B3.96B47%
EBITDA-205.66M-559.57M37%
Gain YTD-1.571-3.41146%
P/E RatioN/AN/A-
Revenue217M0-
Total Cash361M502M72%
Total Debt345M4.09M8,443%
FUNDAMENTALS RATINGS
SNDX vs VKTX: Fundamental Ratings
SNDX
VKTX
OUTLOOK RATING
1..100
1617
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
7976
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
4547
P/E GROWTH RATING
1..100
4100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VKTX's Valuation (50) in the Biotechnology industry is somewhat better than the same rating for SNDX (97). This means that VKTX’s stock grew somewhat faster than SNDX’s over the last 12 months.

VKTX's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as SNDX (79). This means that VKTX’s stock grew similarly to SNDX’s over the last 12 months.

VKTX's SMR Rating (99) in the Biotechnology industry is in the same range as SNDX (100). This means that VKTX’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Price Growth Rating (45) in the Biotechnology industry is in the same range as VKTX (47). This means that SNDX’s stock grew similarly to VKTX’s over the last 12 months.

SNDX's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for VKTX (100). This means that SNDX’s stock grew significantly faster than VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SNDXVKTX
RSI
ODDS (%)
Bullish Trend 5 days ago
90%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 12 days ago
76%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
SNDX
Daily Signal:
Gain/Loss:
VKTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SSK14.180.82
+6.14%
REX-Osprey SOL + Staking ETF
UPSX13.730.31
+2.31%
Tradr 2X Long UPST Daily ETF
WMTI19.450.27
+1.41%
REX WMT Growth & Income ETF
RDIV63.260.24
+0.38%
Invesco S&P Ultra Dividend Revenue ETF
CGUI25.29N/A
N/A
Capital Group Ultra Short Income ETF